Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bio Medica LaboratoriesNSE:BMLL +1.21%18 Return-on-Tangible-Asset is 33.40% as of Mar. 2025, which is 148% above its 10-year median of 13.47. GuruFocus rates NSE:BMLL with a GF Score™ of 18/100. The stock has 7 warning signs investors should review. Among 855 Medical Devices & Instruments companies, Bio Medica Laboratories ranks better than 98.36% on this metric.
Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Bio Medica Laboratories's annualizedNet Income for the quarter that ended in Mar. 2025 was ₹97.9 Mil. Bio Medica Laboratories's average total tangible assets for the quarter that ended in Mar. 2025 was ₹293.2 Mil. Therefore, Bio Medica Laboratories's annualized Return-on-Tangible-Asset for the quarter that ended in Mar. 2025 was 33.40%.
The historical rank and industry rank for Bio Medica Laboratories's Return-on-Tangible-Asset or its related term are showing as below:
NSE:BMLL'
s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: 1.9 Med: 13.47 Max: 33.4
Current: 33.4
During the past 3 years, Bio Medica Laboratories's highest Return-on-Tangible-Asset was 33.40%. The lowest was 1.90%. And the median was 13.47%.
NSE:BMLL's Return-on-Tangible-Asset is ranked better than 98.36% of 855
companies
in the Medical Devices & Instruments industry
Industry Median: 0.74
vs NSE:BMLL: 33.40
Bio Medica Laboratories (NSE:BMLL) Return-on-Tangible-Asset Explanation
Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.
Be Aware
Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the companys earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a companys tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.
Bio Medica Laboratories Return-on-Tangible-Asset Related Terms
Bio Medica Laboratories Return-on-Tangible-Asset Historical Data
* Premium members only.
The historical data trend for Bio Medica Laboratories's Return-on-Tangible-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio Medica Laboratories Return-on-Tangible-Asset Chart
Bio Medica Laboratories Annual Data
Trend
Mar23
Mar24
Mar25
Return-on-Tangible-Asset
1.90
13.47
33.40
Bio Medica Laboratories Semi-Annual Data
Mar23
Mar24
Mar25
Return-on-Tangible-Asset
1.90
13.47
33.40
NSE:BMLL vs ISRG, BDX, MDLN: Return-on-Tangible-Asset Comparison
For the Medical Instruments & Supplies subindustry, Bio Medica Laboratories's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bio Medica Laboratories Return-on-Tangible-Asset vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Bio Medica Laboratories's Return-on-Tangible-Asset distribution charts can be found below:
* The bar in red indicates where Bio Medica Laboratories's Return-on-Tangible-Asset falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is one times the annual (Mar. 2025) net income data.
What does a Return-on-Tangible-Asset of 33.40% mean?
Bio Medica Laboratories (NSE:BMLL) has a Return-on-Tangible-Asset of 33.40% as of Mar. 2025. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bio Medica Laboratories and its competitors. This is 148% above median its historical median of 13.47. Over the past decade, Bio Medica Laboratories' Return-on-Tangible-Asset has ranged from 1.90 to 33.40. According to the industry distribution chart, Bio Medica Laboratories ranks #14 out of 855 companies in the Medical Devices & Instruments industry, placing it in the top 1.6%.
Is Bio Medica Laboratories' Return-on-Tangible-Asset too high?
Bio Medica Laboratories' current Return-on-Tangible-Asset of 33.40% is 148% above median its 10-year median of 13.47. Over the past 10 years, this metric has ranged from a low of 1.90 to a high of 33.40. The Medical Devices & Instruments industry median Return-on-Tangible-Asset is 0.74. Bio Medica Laboratories' value of 33.40% is 4413.5% above this industry median. Based on the distribution chart, Bio Medica Laboratories ranks #14 out of 855 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Bio Medica Laboratories has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Bio Medica Laboratories' Return-on-Tangible-Asset compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Bio Medica Laboratories ranks #14 out of 855 companies for Return-on-Tangible-Asset. This places Bio Medica Laboratories in the top 2% of its industry — outperforming the majority of peers. The industry median Return-on-Tangible-Asset is 0.74. Bio Medica Laboratories' value of 33.40% is 4413.5% above this benchmark. Historically, Bio Medica Laboratories' own Return-on-Tangible-Asset has ranged from 1.90 to 33.40 over the past decade. While the company's 10-year median is 13.47 vs. the industry median of 0.74, Bio Medica Laboratories has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Asset for a Medical Devices & Instruments company?
The median Return-on-Tangible-Asset among Medical Devices & Instruments companies is 0.74, based on 855 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Asset significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bio Medica Laboratories's current Return-on-Tangible-Asset of 33.40% is 4413.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Asset mean?
A high Return-on-Tangible-Asset can signal that a stock is expensive relative to its fundamentals. Return on tangible assets is the ratio of current-period net income to average two-period tangible assets. View historical data on Bio Medica Laboratories and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Asset is 0.74 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bio Medica Laboratories's current Return-on-Tangible-Asset is 33.40%, which is 148% above median its own 10-year median of 13.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bio Medica Laboratories stock overvalued right now?
Bio Medica Laboratories (NSE:BMLL) has a current Return-on-Tangible-Asset of 33.40%. The current Return-on-Tangible-Asset is 33.40%, which is 148% above median its 10-year median of 13.47 and 4413.5% above the Medical Devices & Instruments industry median of 0.74. Bio Medica Laboratories' overall GF Score™ is 18/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Asset calculated?
Return-on-Tangible-Asset is calculated from a company's financial statements. For Bio Medica Laboratories (NSE:BMLL), the current Return-on-Tangible-Asset is 33.40% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bio Medica Laboratories Ltd is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. It manufactures generic drugs in the form of injectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both single dose and multi dose forms, catering both human and veterinary needs. Its products address a wide range of medical needs and preferences. The majority of revenue is derived from the sales of Liquid injections. Geographically, it operates predominantly in India, and internationally, it exports to Afghanistan.
18GF Score
Get the complete analysis for NSE:BMLL
Return-on-Tangible-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:BMLL has been successfully added to your 
